1/2: 5 year efficacy & biomarker data for axitinib/pembro in 1st line clear cell RCC. OncoAlert Significant ⬆️ RR PFS & OS in the ITT population means this combo is as good as any in this setting. None of the biomarkers tested (RNA, DNA PR) will change clinical practice.

Key lung cancer 🫁 milestones to watch in 2025. 🔗 Follow us for latest clinical trials and insights from the world of oncology 👉 clin.larvol.com #LARVOL #LungCancer #WorldLungCancerDay #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights #WLCD |

Are we ready for artificial intelligence in pathology? AIM-PD-L1 is an #AI model for digital PD-L1 scoring. Report JTO & JTO CRR compared digital to manual using NSCLC samples from IMpower 110 + 150 & showed high concordance and predicted clinical outcomes. jto.org/article/S1556-…

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901) thelancet.com/journals/lanon… This prespecified substudy of the ENZA-p phase 2 trial evaluated whether baseline quantitative

Science doesn’t need to go according to plan; it just needs to lead to a discovery. If doesn’t have to be done alone or together with a buddy; there just needs to be a discovery. It doesn’t need to happen fast or slow; just as long as there’s a discovery, then everybody is happy.

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…

Treatment of NSCLC after chemoimmunotherapy — are we making headway? Excellent review👇 nature.com/articles/s4157…

SAVANNAH : Ph II Savolitinib+osi in EGFR-mut #NSCLC with MET IHC+++ (>90%) and/or FISH>10 after PD on osi: Out in ESMO - Eur. Oncology AoO: N=80 ORR=56.3%, mDoR=7.1m mPFS=7.4m Oedema 46%, diarrhea 23.2% A valid option for a strictly defined pt population #some #LCSM EGFR Positive Lung Cancer UK EGFRm NSCLC

🚨 Trials to Watch – WCLC 2025 🚨 🔑 Plenary LBAs: FLAURA2: Osimertinib + Chemo (OS update) Aumolertinib + Chemo (EGFRm NSCLC) HARMONi-A: Ivonescimab + Chemo vs Chemo ARROS-1: Zidesamtinib (ROS1+) CheckMate 816: Neoadjuvant Nivolumab (OS) EA5181: Durvalumab + CRT in Stage III

IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last natera.com/company/news/i…

Great to share this first piece from my Common Sense Oncology fellowship, written with Bishal Gyawali, MD, PhD, FASCO. We use some issues with CodeBreaK300 to argue that the promise of precision medicines are only fulfilled when coupled with precision in design, analysis and reporting of trials.

Up to 50% of patients with metastatic cancer develop lung metastases, linked to poor prognosis and impaired quality of life. Our Nature Reviews Disease Primers article unpacks biology, diagnosis & treatment strategies. Lodovica Zullo Gustave Roussy nature.com/articles/s4157…

Mayo Clinic retrospective analysis: Induction chemo+ IO → cCRT → +/- maintenance ICI appears feasible in stage III NSCLC patients not suitable for upfront cCRT (n:29) ORR➡️ 93% (induction phase) mPFS➡️18 mo mOS➡️24 mo ❗️Adverse events: pneumonitis 37.9% (≥grade 3: 18%),

Increasing need to consider using transcriptome signatures to provide clinically important information in advanced prostate cancers eg. PTEN inactivated cancers may have greater benefits with docetaxel use.

🧬 De-escalation in #NSCLC: optimizing targeted therapy in EGFR & ALK disease: cancertreatmentreviews.com/article/S0305-… 1️⃣ Feasible & safe 2️⃣Arbitrary regimens = ↑ toxicity without ↑ efficacy 3️⃣↓ toxicity & cost, preserve outcomes Sometimes, it’s targeted minimalism that hits the mark 🎯

🚨 Just a few days to WCLC 2025! IASLC Barcelona will host a pivotal gathering of lung cancer experts. Get ready for breakthroughs across thoracic oncology. Here are some of the key abstracts to watch! 👇🏻 #WCLC25 #CánCare #lungcancer #NSCLC #SCLC #thoraciconcology

FLAURA2 discussed at WCLC plenary: almost 10 mths OS difference with frontline combi of chemo with osi vs osi alone HR 0.77. Agree we need a road map to have better risk stratification for EGFR mut lung ca pt to review treatment intensification vs trade-offs with added toxicities

More treatment options now for uncommon EGFR mutations and exon 20 insertion NSCLC #wclc2025

EA5181 showed no added benefit for concurrent administration of durvalumab with CRT hence Pacific regimen remains SOC at this point in time. #wclc2025

A truly unforgettable evening at the IASLC celebration night set against the most amazing Barcelona skyline @ Tibidabo! Amazing IASLC managed to secure such a stunning spot for all of us to enjoy great food, drinks and even access the fun theme park rides! #WCLC2025